Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042595 | 1.00 | ACE (0.53) | ACEACE2L3MBTL1MEN1KMT2A | |
| SCHEMBL5040361 | 1.00 | ACE (0.53) | ACEACE2L3MBTL1MEN1KMT2A | |
| SCHEMBL10537401 | 1.00 | ACE (0.53) | ACEACE2L3MBTL1MEN1KMT2A | |
| SCHEMBL5042617 | 1.00 | ACE (0.53) | ACEACE2L3MBTL1MEN1KMT2A | |
| SCHEMBL5035966 | 1.00 | ACE (0.53) | ACEACE2L3MBTL1MEN1KMT2A | |
| SCHEMBL5040398 | 1.00 | ACE (0.53) | ACEACE2L3MBTL1MEN1KMT2A | |
| SCHEMBL5035700 | 1.00 | ACE (0.53) | ACEACE2L3MBTL1MEN1KMT2A | |
| SCHEMBL10535708 | 1.00 | ACE (0.53) | ACEACE2L3MBTL1MEN1KMT2A | |
| SCHEMBL5035965 | 1.00 | ACE (0.53) | ACEACE2L3MBTL1MEN1KMT2A | |
| SCHEMBL5035703 | 1.00 | ACE (0.53) | ACEACE2L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263730-B1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | SERONO LAB (CH) | 2008-01-09 | — | — | EP | claimed |
| US-6770656-B2 | NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2004-08-03 | — | — | US | claimed |
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | MERCK SERONO SA (CH) | 2003-11-20 | — | — | US | claimed |
| EP-1263730-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | Applied Research Systems ARS Holding N.V. (AN) | 2002-12-11 | — | — | EP | claimed |
| WO-2001060798-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-08-23 | — | — | WO | claimed |
| EP-1263730-B1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | SERONO LAB (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-6770656-B2 | NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2004-08-03 | — | — | US | disclosed |
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | MERCK SERONO SA (CH) | 2003-11-20 | — | — | US | disclosed |
| EP-1263730-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | Applied Research Systems ARS Holding N.V. (AN) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001060798-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-08-23 | — | — | WO | disclosed |
| US-4837026-A | Transdermal and systemic preparation and method | THERAPEUTIC PATCH RESEARCH N.V. | 1989-06-06 | — | — | US | disclosed |
| EP-0240554-A1 | TRANSDERMAL AND SYSTEMIC PREPARATION AND METHOD | RAJADHYAKSHA, Vithal J. (US) | 1987-10-14 | — | — | EP | disclosed |
| WO-1987001935-A1 | TRANSDERMAL AND SYSTEMIC PREPARATION AND METHOD | RAJADHYAKSHA VITHAL J | 1987-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | BAD, BAX, BCL2 | ACE 3869/4885ACE2 3998/4885L3MBTL1 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.